epigallocatechin gallate has been researched along with Acute Respiratory Distress Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grebenchikov, OA; Zinovkin, RA | 1 |
| Bu, D; Gong, ZN; Wang, YF; Xu, GL; Yao, L; Yu, SQ; Zhang, SQ | 1 |
2 other study(ies) available for epigallocatechin gallate and Acute Respiratory Distress Syndrome
| Article | Year |
|---|---|
Transcription Factor Nrf2 as a Potential Therapeutic Target for Prevention of Cytokine Storm in COVID-19 Patients.
Topics: Animals; Antioxidants; Betacoronavirus; Catechin; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Dimethyl Fumarate; Female; Humans; Immunosuppressive Agents; Inflammation; Isothiocyanates; Male; Mice; Molecular Targeted Therapy; NF-E2-Related Factor 2; Oxidative Stress; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; Resveratrol; SARS-CoV-2; Signal Transduction; Sulfoxides; Thiosulfates | 2020 |
[Effect of epigallocatechingallate on acute lung injury induced by oleic acid in mice].
Topics: Animals; Catechin; Lung; Male; Mice; Oleic Acid; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protective Agents; Respiratory Distress Syndrome; Tumor Necrosis Factor-alpha | 2005 |